JPWO2022131198A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022131198A5 JPWO2022131198A5 JP2022569975A JP2022569975A JPWO2022131198A5 JP WO2022131198 A5 JPWO2022131198 A5 JP WO2022131198A5 JP 2022569975 A JP2022569975 A JP 2022569975A JP 2022569975 A JP2022569975 A JP 2022569975A JP WO2022131198 A5 JPWO2022131198 A5 JP WO2022131198A5
- Authority
- JP
- Japan
- Prior art keywords
- tyrosine kinase
- dipeptidyl peptidase
- inhibitor
- kinase inhibitor
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 10
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 10
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 8
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 claims 6
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 claims 6
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 6
- 206010038389 Renal cancer Diseases 0.000 claims 6
- 201000010982 kidney cancer Diseases 0.000 claims 6
- 230000001225 therapeutic effect Effects 0.000 claims 5
- 229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 claims 4
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 239000003623 enhancer Substances 0.000 claims 3
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 2
- LCDDAGSJHKEABN-MLGOLLRUSA-N Evogliptin Chemical compound C1CNC(=O)[C@@H](COC(C)(C)C)N1C(=O)C[C@H](N)CC1=CC(F)=C(F)C=C1F LCDDAGSJHKEABN-MLGOLLRUSA-N 0.000 claims 2
- ZWPRRQZNBDYKLH-VIFPVBQESA-N Gemigliptin Chemical compound C([C@@H](N)CC(=O)N1CC2=C(C(=NC(=N2)C(F)(F)F)C(F)(F)F)CC1)N1CC(F)(F)CCC1=O ZWPRRQZNBDYKLH-VIFPVBQESA-N 0.000 claims 2
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims 2
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 2
- 239000003798 L01XE11 - Pazopanib Substances 0.000 claims 2
- 239000002176 L01XE26 - Cabozantinib Substances 0.000 claims 2
- LTXREWYXXSTFRX-QGZVFWFLSA-N Linagliptin Chemical compound N=1C=2N(C)C(=O)N(CC=3N=C4C=CC=CC4=C(C)N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 LTXREWYXXSTFRX-QGZVFWFLSA-N 0.000 claims 2
- 229960001667 alogliptin Drugs 0.000 claims 2
- ZSBOMTDTBDDKMP-OAHLLOKOSA-N alogliptin Chemical compound C=1C=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 ZSBOMTDTBDDKMP-OAHLLOKOSA-N 0.000 claims 2
- 229950009977 anagliptin Drugs 0.000 claims 2
- LDXYBEHACFJIEL-HNNXBMFYSA-N anagliptin Chemical compound C=1N2N=C(C)C=C2N=CC=1C(=O)NCC(C)(C)NCC(=O)N1CCC[C@H]1C#N LDXYBEHACFJIEL-HNNXBMFYSA-N 0.000 claims 2
- 229960003005 axitinib Drugs 0.000 claims 2
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 claims 2
- 229960001292 cabozantinib Drugs 0.000 claims 2
- ONIQOQHATWINJY-UHFFFAOYSA-N cabozantinib Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 ONIQOQHATWINJY-UHFFFAOYSA-N 0.000 claims 2
- 229940000425 combination drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229950011259 evogliptin Drugs 0.000 claims 2
- 229960002458 gemigliptin Drugs 0.000 claims 2
- 229950005754 gosogliptin Drugs 0.000 claims 2
- QWEWGXUTRTXFRF-KBPBESRZSA-N gosogliptin Chemical compound C1C(F)(F)CCN1C(=O)[C@H]1NC[C@@H](N2CCN(CC2)C=2N=CC=CN=2)C1 QWEWGXUTRTXFRF-KBPBESRZSA-N 0.000 claims 2
- 229960003784 lenvatinib Drugs 0.000 claims 2
- WOSKHXYHFSIKNG-UHFFFAOYSA-N lenvatinib Chemical compound C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 WOSKHXYHFSIKNG-UHFFFAOYSA-N 0.000 claims 2
- 229960002397 linagliptin Drugs 0.000 claims 2
- 229950000074 omarigliptin Drugs 0.000 claims 2
- MKMPWKUAHLTIBJ-ISTRZQFTSA-N omarigliptin Chemical compound C1([C@H]2OC[C@@H](C[C@@H]2N)N2CC3=CN(N=C3C2)S(=O)(=O)C)=CC(F)=CC=C1F MKMPWKUAHLTIBJ-ISTRZQFTSA-N 0.000 claims 2
- 229960000639 pazopanib Drugs 0.000 claims 2
- CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 claims 2
- 229960004937 saxagliptin Drugs 0.000 claims 2
- QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 claims 2
- 108010033693 saxagliptin Proteins 0.000 claims 2
- 229960004034 sitagliptin Drugs 0.000 claims 2
- MFFMDFFZMYYVKS-SECBINFHSA-N sitagliptin Chemical compound C([C@H](CC(=O)N1CC=2N(C(=NN=2)C(F)(F)F)CC1)N)C1=CC(F)=C(F)C=C1F MFFMDFFZMYYVKS-SECBINFHSA-N 0.000 claims 2
- 229960003787 sorafenib Drugs 0.000 claims 2
- 229960001796 sunitinib Drugs 0.000 claims 2
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims 2
- 229950000034 teneligliptin Drugs 0.000 claims 2
- WGRQANOPCQRCME-PMACEKPBSA-N teneligliptin Chemical compound O=C([C@H]1NC[C@H](C1)N1CCN(CC1)C1=CC(=NN1C=1C=CC=CC=1)C)N1CCSC1 WGRQANOPCQRCME-PMACEKPBSA-N 0.000 claims 2
- 229950010728 trelagliptin Drugs 0.000 claims 2
- IWYJYHUNXVAVAA-OAHLLOKOSA-N trelagliptin Chemical compound C=1C(F)=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 IWYJYHUNXVAVAA-OAHLLOKOSA-N 0.000 claims 2
- 108700026220 vif Genes Proteins 0.000 claims 2
- 229960001254 vildagliptin Drugs 0.000 claims 2
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020206499 | 2020-12-14 | ||
| PCT/JP2021/045772 WO2022131198A1 (ja) | 2020-12-14 | 2021-12-13 | 腎がんを治療するための併用医薬及びチロシンキナーゼ阻害薬の治療効果増強剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2022131198A1 JPWO2022131198A1 (https=) | 2022-06-23 |
| JPWO2022131198A5 true JPWO2022131198A5 (https=) | 2023-09-28 |
Family
ID=82057787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022569975A Pending JPWO2022131198A1 (https=) | 2020-12-14 | 2021-12-13 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20240148736A1 (https=) |
| EP (1) | EP4260873A4 (https=) |
| JP (1) | JPWO2022131198A1 (https=) |
| WO (1) | WO2022131198A1 (https=) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11583516B2 (en) * | 2016-09-07 | 2023-02-21 | Trustees Of Tufts College | Dash inhibitors, and uses related thereto |
-
2021
- 2021-12-13 US US18/257,140 patent/US20240148736A1/en active Pending
- 2021-12-13 JP JP2022569975A patent/JPWO2022131198A1/ja active Pending
- 2021-12-13 EP EP21906560.4A patent/EP4260873A4/en active Pending
- 2021-12-13 WO PCT/JP2021/045772 patent/WO2022131198A1/ja not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| A Jaso et al. | Therapeutic modulation of glutamate receptors in major depressive disorder | |
| MX2024000208A (es) | Restos de administracion terapeutica novedosos y usos de estos. | |
| JP2023533464A5 (https=) | ||
| UA94097C2 (ru) | Пиридил- и пиримидинилзамещенные производной пиррола, тиофена и фурана как ингибиторы киназ | |
| RU2014110184A (ru) | Комбинации терапевтических средств, предназначенные для лечения рака | |
| WO2019058348A1 (en) | COMBINATION OF A BTK INHIBITOR AND A CDK9 INHIBITOR TO TREAT CANCER | |
| EP2729146A1 (en) | Medicament for treatment of liver cancer | |
| KR102147721B1 (ko) | 스트렙토니그린 및 라파마이신을 유효성분으로 포함하는, 암 예방 또는 치료용 약학적 조성물 | |
| US20150119351A1 (en) | Therapy of tumors and infectious agents deficient in methylthioadenosine phosphorylase | |
| CN112512527A (zh) | 恩扎妥林和btk抑制剂的组合及其用途 | |
| JP2022505041A5 (https=) | ||
| EA202192180A1 (ru) | Ингибитор киназы atr bay 1895344 для применения для лечения гиперпролиферативного заболевания | |
| JP2011500776A5 (https=) | ||
| Batiha et al. | Favipiravir in SARS-CoV-2 infection: is it worth it? | |
| JP2017515847A5 (https=) | ||
| RU2015124954A (ru) | Фармацевтические комбинации | |
| GB0328180D0 (en) | Combination | |
| JP2016501222A5 (https=) | ||
| JPWO2022131198A5 (https=) | ||
| JP2014534229A5 (https=) | ||
| WO2008033754A3 (en) | Xanthine derivatives in methods and compositions for the treatment of vascular depression | |
| JP2018522049A5 (https=) | ||
| AR086675A1 (es) | Composiciones farmaceuticas de combinaciones de inhibidores de la dipeptidil peptidasa-4 con simvastatina | |
| BR112022013492A2 (pt) | Terapia de combinação para tratar câncer | |
| WO2002053096A3 (en) | Single therapy and combination therapy involving drugs with target cellular proteins and drugs which target pathogen-encoded proteins |